Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity

24 Jun 1997

Abstract excerpt

We have developed an immunotherapy in which tumor cells transfected with syngeneic major histocompatibility complex (MHC) class II genes are cell-based vaccines for the treatment of established tumor and metastatic disease. If this strategy is to be used clinically, convenient methods for generating class II+ tumor cells are necessary. Interferon-gamma treatment or transduction of the class II transactivator...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 9192661
DOI: 10.1073/pnas.94.13.6886

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunityPMID 9192661Read ↗

MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes.Semantic proximity Read ↗

Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells.Semantic proximity Read ↗

Invariant chain alters the malignant phenotype of MHC class II+ tumor cells.Semantic proximity Read ↗

CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.Semantic proximity Read ↗

Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity.Semantic proximity Read ↗

Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.Semantic proximity Read ↗

Dendritic cell-tumor fusion vaccine prevents tumor growth in vivo.Semantic proximity Read ↗

Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4<sup>+</sup> T‐cell‐independent CD8<sup>+</sup> T‐cell‐mediated tumor controlSemantic proximity Read ↗

MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator.Semantic proximity Read ↗

Induction of antigen specific CD4+ T cell responses by invariant chain based DNA vaccines.Semantic proximity Read ↗

Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors.Semantic proximity Read ↗

Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.